These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 32358715

  • 41. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
    Lasota J, Kowalik A, Wasag B, Wang ZF, Felisiak-Golabek A, Coates T, Kopczynski J, Gozdz S, Miettinen M.
    Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
    [Abstract] [Full Text] [Related]

  • 42. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW.
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
    [Abstract] [Full Text] [Related]

  • 43. A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.
    Martinuzzi C, Pastorino L, Andreotti V, Garuti A, Minuto M, Fiocca R, Bianchi-Scarrà G, Ghiorzo P, Grillo F, Mastracci L.
    Endocrine; 2016 Sep; 53(3):672-80. PubMed ID: 26296380
    [Abstract] [Full Text] [Related]

  • 44. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
    Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, Kim SW.
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
    [Abstract] [Full Text] [Related]

  • 45. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma.
    Qi W, Shi C, Zhang P, Feng L, Wang J, Chen D.
    Pathol Res Pract; 2020 Aug; 216(8):153037. PubMed ID: 32703500
    [Abstract] [Full Text] [Related]

  • 46. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H, Zhang ZH, Zhou B, Xiao T, Pan QJ, Guo HQ.
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [Abstract] [Full Text] [Related]

  • 47. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA, Murad F, Dawson E, Abd Elmageed ZY, Tsumagari K, Kandil E.
    J Surg Res; 2016 Jun 15; 203(2):407-15. PubMed ID: 27363650
    [Abstract] [Full Text] [Related]

  • 48. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
    Hang JF, Chen JY, Kuo PC, Lai HF, Lee TL, Tai SK, Kuo CS, Chen HS, Li WS, Li CF.
    Mod Pathol; 2023 Sep 15; 36(9):100242. PubMed ID: 37307878
    [Abstract] [Full Text] [Related]

  • 49. Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.
    Smith AL, Williams MD, Stewart J, Wang WL, Krishnamurthy S, Cabanillas ME, Roy-Chowdhuri S.
    Cancer Cytopathol; 2018 Jun 15; 126(6):406-413. PubMed ID: 29579361
    [Abstract] [Full Text] [Related]

  • 50. The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing.
    Yeo MK, Jung MK, Lee SY, Lee YM, Hur GM, Kim JM.
    J Clin Pathol; 2017 Mar 15; 70(3):260-265. PubMed ID: 27543599
    [Abstract] [Full Text] [Related]

  • 51. Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features.
    Wahid MHA, Almudhafar RH.
    J Med Life; 2022 Apr 15; 15(4):520-525. PubMed ID: 35646190
    [Abstract] [Full Text] [Related]

  • 52. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
    Kuan SF, Navina S, Cressman KL, Pai RK.
    Hum Pathol; 2014 Mar 15; 45(3):464-72. PubMed ID: 24529329
    [Abstract] [Full Text] [Related]

  • 53. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A, Ramshankar V, Murherkar K, Vidyarani S, Raghunandhan GC, Das A, Desai PB, Albert K.
    Indian J Cancer; 2017 Mar 15; 54(1):372-378. PubMed ID: 29199726
    [Abstract] [Full Text] [Related]

  • 54. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
    Leblond AL, Rechsteiner M, Jones A, Brajkovic S, Dupouy D, Soltermann A.
    Am J Clin Pathol; 2019 Jun 05; 152(1):59-73. PubMed ID: 31065676
    [Abstract] [Full Text] [Related]

  • 55. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
    Gao J, Ma XP, Deng FS, Jiang L, Jia WD, Li M.
    Pathol Oncol Res; 2020 Jul 05; 26(3):1833-1841. PubMed ID: 31758408
    [Abstract] [Full Text] [Related]

  • 56. Assessment of BRAF V600E (VE1) immunochemistry for the detection of BRAF V600E mutation in non-small cell lung carcinoma cytology specimens.
    Garcia A, Rivera Rolon MDM, Barkoh B, Chen W, Luthra R, Roy-Chowdhuri S.
    Cancer Cytopathol; 2023 Jan 05; 131(1):50-57. PubMed ID: 36200799
    [Abstract] [Full Text] [Related]

  • 57. Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues.
    Zhang Y, Liu L, Liu Y, Cao N, Wang L, Xing C.
    Medicine (Baltimore); 2021 Apr 23; 100(16):e25566. PubMed ID: 33879712
    [Abstract] [Full Text] [Related]

  • 58. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters.
    Kombak FE, Özkan N, Uğurlu MÜ, Kaya H.
    Turk Patoloji Derg; 2019 Apr 23; 35(2):83-91. PubMed ID: 30632125
    [Abstract] [Full Text] [Related]

  • 59. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
    Ilie MI, Long-Mira E, Hofman V, Mouroux J, Vignaud JM, Gauchotte G, Begueret H, Merlio JP, Emile JF, Hébuterne X, Hofman P.
    Pathology; 2014 Jun 23; 46(4):311-5. PubMed ID: 24798160
    [Abstract] [Full Text] [Related]

  • 60. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
    Ida CM, Vrana JA, Rodriguez FJ, Jentoft ME, Caron AA, Jenkins SM, Giannini C.
    Acta Neuropathol Commun; 2013 May 30; 1():20. PubMed ID: 24252190
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.